期刊
JOURNAL OF LIPID RESEARCH
卷 58, 期 8, 页码 1598-1612出版社
ELSEVIER
DOI: 10.1194/jlr.M075531
关键词
triglycerides; metabolic disease; diseases; drug therapy; protein-membrane interactions; membrane lipid therapy; triheptanoin; adult polyglucosan body disease
资金
- Spanish Ministerio de Economia y Competitividad [BIO-2013-49006-C2-1-R, RTC-2015-3542-1, RTC-2015-4094-1]
- Marathon Foundation
- Adult Polyglucosan Body Disease Research Foundation
- FEDER funds from the EU (Una manera de hacer Europa)
Adult polyglucosan body disease (APBD) is a neurological disorder characterized by adult-onset neurogenic bladder, spasticity, weakness, and sensory loss. The disease is caused by aberrant glycogen branching enzyme (GBE) (GBE1Y329S) yielding less branched, globular, and soluble glycogen, which tends to aggregate. We explore here whether, despite being a soluble enzyme, GBE1 activity is regulated by protein-membrane interactions. Because soluble proteins can contact a wide variety of cell membranes, we investigated the interactions of purified WT and GBE1Y329S proteins with different types of model membranes (liposomes). Interestingly, both triheptanoin and some triacylglycerol mimetics (TGMs) we have designed (TGM0 and TGM5) markedly enhance GBE1Y329S activity, possibly enough for reversing APBD symptoms. We show that the GBE1Y329S mutation exposes a hydrophobic amino acid stretch, which can either stabilize and enhance or alternatively, reduce the enzyme activity via alteration of protein-membrane interactions. Additionally, we found that WT, but not Y329S, GBE1 activity is modulated by Ca2+ and phosphatidylserine, probably associated with GBE1-mediated regulation of energy consumption and storage. The thermal stabilization and increase in GBE1Y329S activity induced by TGM5 and its omega-3 oil structure suggest that this molecule has a considerable therapeutic potential for treating APBD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据